Statusphere | $18,000,000 | (Jan 21, 2026)
Think Bioscience | $55,000,000 | (Jan 21, 2026)
Certified by Founder
Lodge
ErVimmune
start up
- 21/01/2026
- Series A
- $19,917,795
Targeting shared unconventional tumor antigens in cancer immunotherapy
- Industry Biotechnology Research
- Website https://ervimmune.com/
- LinkedIn https://www.linkedin.com/company/ervimmune/
Related People
Stéphane DEPILFounder
France -
Onco-hematologist at Centre Léon Bérard and leader of the team "Antigen presentation, T cell and Cancer" at Cancer Research Center of Lyon. Over 20 years of experience in oncology research and drug development both in academia and pharma/biotech companies as former SVP R&D and CMO at Cellectis, CEO at Netris Pharma and Head of OncologyR&D at Servier.Founder and board member of ErVimmune, a biotech company developing cancer vaccines and T cell therapies targeting non-conventional tumor epitopes.
POINT.LAZ | $3,000,000 | (Jan 21, 2026)
Jetson(CANADA) | $50,000,000 | (Jan 21, 2026)
BrightInsight | $13,000,000 | (Jan 21, 2026)
Formulary Financial | $4,600,000 | (Jan 21, 2026)
Ultra Pouches | $11,000,000 | (Jan 21, 2026)
XBuild | $19,000,000 | (Jan 21, 2026)
Dam Secure | $4,000,000 | (Jan 21, 2026)
Infinitopes | $15,400,000 | (Jan 21, 2026)
Cosmos | $15,000,000 | (Jan 21, 2026)